{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:10:30Z","timestamp":1778904630229,"version":"3.51.4"},"reference-count":28,"publisher":"Pharmaceutical Society of Japan","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,5,14]]},"DOI":"10.1248\/bpb.b25-00791","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:09:55Z","timestamp":1778710195000},"page":"809-817","source":"Crossref","is-referenced-by-count":0,"title":["Economic Burden of Cachexia in Japanese Lung Cancer Patients: A Retrospective Claims Database Analysis"],"prefix":"10.1248","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5178-611X","authenticated-orcid":false,"given":"Munenobu","family":"Kashiwa","sequence":"first","affiliation":[{"name":"Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Research Organization of Science and Technology, Ritsumeikan University, Kusatsu, Shiga 525\u20138527, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. <i>Lancet Oncol.<\/i>, <b>12<\/b>, 489\u2013495 (2011).","DOI":"10.1016\/S1470-2045(10)70218-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Takaoka T, Yaegashi A, Watanabe D. Prevalence of and survival with cachexia among patients with cancer: a systematic review and meta-analysis. <i>Adv. Nutr.<\/i>, <b>15<\/b>, 100282 (2024).","DOI":"10.1016\/j.advnut.2024.100282"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. <i>Nat. Rev. Dis. Primers<\/i>, <b>4<\/b>, 17106 (2018).","DOI":"10.1038\/nrdp.2017.105"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Zhang H, Zhang Y, Tang X, Zhang S, Man C, Gong D, Fan Y. The prevalence and prognostic impact of cancer cachexia on overall survival in patients with gastrointestinal cancer: a meta-analysis. <i>Nutr. Cancer<\/i>, <b>77<\/b>, 590\u2013599 (2025).","DOI":"10.1080\/01635581.2025.2492126"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Arai H, Maeda K, Wakabayashi H, <i>et al<\/i>. Diagnosis and outcomes of cachexia in Asia: working consensus report from the Asian Working Group for Cachexia. <i>J. Cachexia Sarcopenia Muscle<\/i>, <b>14<\/b>, 1949\u20131958 (2023).","DOI":"10.1002\/jcsm.13323"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Yasunaga H. Real world data in Japan: Chapter II the diagnosis procedure combination database. <i>Ann. Clin. Epidemiol.<\/i>, <b>1<\/b>, 76\u201379 (2019).","DOI":"10.37737\/ace.1.3_76"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Granda-Cameron C, DeMille D, Lynch MP, Huntzinger C, Alcorn T, Levicoff J, Roop C, Mintzer D. An interdisciplinary approach to manage cancer cachexia. <i>Clin. J. Oncol. Nurs.<\/i>, <b>14<\/b>, 72\u201380 (2010).","DOI":"10.1188\/10.CJON.72-80"},{"key":"8","unstructured":"8) National Cancer Center. \u201cCancer Statistics. Cancer Information Service, National Cancer Center, Japan (National Cancer Registry, Ministry of Health, Labour and Welfare).\u201d: &lt;https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/summary.html&gt;, accessed 1 July, 2024."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Koizumi T, Nishino Y, Takiguchi T, Kanda S, Otsuki K, Tanaka Y, Tomita R, Araki T, Hayashi R, Yasumoto K, Uramoto H, Hirono Y, Makino T, Nakada M, Yano S. Epidemiological and therapeutic analyses in lung cancer patients over 80 years old in the Hokushin region: a retrospective hospital administrative database study. <i>Clin. Lung Cancer<\/i>, <b>24<\/b>, 145\u2013152 (2023).","DOI":"10.1016\/j.cllc.2022.12.001"},{"key":"10","unstructured":"10) Riely GJ, Wood DE, Ettinger DS, <i>et al<\/i>. Non-small cell lung cancer, version 4.2024, NCCN Clinical Practice Guidelines in Oncology. <i>J. Natl. Compr. Canc. Netw.<\/i>, <b>22<\/b>, 249\u2013274 (2024)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Hasegawa M, Komoto S, Shiroiwa T, Fukuda T. Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system. <i>Value Health<\/i>, <b>23<\/b>, 43\u201351 (2020).","DOI":"10.1016\/j.jval.2019.10.005"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Nagai K, Tanaka T, Kodaira N, Kimura S, Takahashi Y, Nakayama T. Data resource profile: JMDC claims database sourced from health insurance societies. <i>J. Gen. Fam. Med.<\/i>, <b>22<\/b>, 118\u2013127 (2021).","DOI":"10.1002\/jgf2.422"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Sato S, Yasunaga H. A review of studies using Japanese nationwide administrative claims databases. <i>Ann. Clin. Epidemiol.<\/i>, <b>5<\/b>, 58\u201364 (2023).","DOI":"10.37737\/ace.23008"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Zhou J, Williams C, Keng MJ, Wu R, Mihaylova B. Estimating costs associated with disease model states using generalized linear models: A tutorial. <i>PharmacoEconomics<\/i>, <b>42<\/b>, 261\u2013273 (2024).","DOI":"10.1007\/s40273-023-01319-x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Franklin M, Lomas J, Walker S, Young T. An educational review about using cost data for the purpose of cost-effectiveness analysis. <i>PharmacoEconomics<\/i>, <b>37<\/b>, 631\u2013643 (2019).","DOI":"10.1007\/s40273-019-00771-y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\u00f8rensen HT, von Elm E, Langan SM. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. <i>PLoS Med.<\/i>, <b>12<\/b>, e1001885 (2015).","DOI":"10.1371\/journal.pmed.1001885"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. <i>Am. J. Clin. Nutr.<\/i>, <b>91<\/b>, 1133S\u20131137S (2010).","DOI":"10.3945\/ajcn.2010.28608C"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Zhong X, Zimmers TA. Sex differences in cancer cachexia. <i>Curr. Osteoporos. Rep.<\/i>, <b>18<\/b>, 646\u2013654 (2020).","DOI":"10.1007\/s11914-020-00628-w"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Shukuya T, Takahashi K, Shintani Y, Miura K, Sekine I, Takayama K, Inoue A, Okamoto I, Kiura K, Kawaguchi T, Yamamoto N, Miyaoka E, Yoshino I, Date H. Epidemiology, risk factors and impact of cachexia on patient outcome: results from the Japanese Lung Cancer Registry Study. <i>J. Cachexia Sarcopenia Muscle<\/i>, <b>14<\/b>, 1274\u20131285 (2023).","DOI":"10.1002\/jcsm.13216"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kajimoto Y, Honda K, Nozawa K, Mukai M, Teng L, Igarashi A. Use of anticancer therapies and economic burden near the end of life in Japan: Results from claims database. <i>JCO Glob. Oncol.<\/i>, <b>8<\/b>, e2200227 (2022).","DOI":"10.1200\/GO.22.00227"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Hiratsuka Y, Oishi T, Miyashita M, Morita T, Mack JW, Sato Y, Takahashi M, Komine K, Saijo K, Ishioka C, Inoue A. Factors related to specialized palliative care use and aggressive care at end of life in Japanese patients with advanced solid cancers: a cohort study. <i>Support. Care. Cancer<\/i>, <b>29<\/b>, 7805\u20137813 (2021).","DOI":"10.1007\/s00520-021-06364-w"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Arthur ST, Van Doren BA, Roy D, Noone JM, Zacherle E, Blanchette CM. Cachexia among U.S. cancer patients. <i>J. Med. Econ.<\/i>, <b>19<\/b>, 874\u2013880 (2016).","DOI":"10.1080\/13696998.2016.1181640"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Naito T, Okayama T, Aoyama T, <i>et al<\/i>. Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study. <i>BMC Cancer<\/i>, <b>17<\/b>, 800 (2017).","DOI":"10.1186\/s12885-017-3795-2"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Khan S, Ahmad Javid S, Ur Rehman S, Akhtar Y, Amir Khan M. A systematic review of cost-effectiveness analyses examining treatments for cachexia syndrome. <i>Nutr. Cancer<\/i>, <b>76<\/b>, 584\u2013595 (2024).","DOI":"10.1080\/01635581.2024.2353939"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, Fallon M, Herrstedt J, Lau H, Platek M, Rugo HS, Schnipper HH, Smith TJ, Tan W, Loprinzi CL. Management of cancer cachexia: ASCO guideline. <i>J. Clin. Oncol.<\/i>, <b>38<\/b>, 2438\u20132453 (2020).","DOI":"10.1200\/JCO.20.00611"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Taniguchi J, Mikura S, da Silva Lopes K. The efficacy and safety of anamorelin for patients with cancer-related anorexia\/cachexia syndrome: a systematic review and meta-analysis. <i>Sci. Rep.<\/i>, <b>13<\/b>, 15257 (2023).","DOI":"10.1038\/s41598-023-42446-x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Chen H, Ishihara M, Kazahari H, Ochiai R, Tanzawa S, Honda T, Ichikawa Y, Horita N, Nagai H, Watanabe K, Seki N. Efficacy and safety of pharmacotherapy for cancer cachexia: a systematic review and network meta-analysis. <i>Cancer Med.<\/i>, <b>13<\/b>, e70166 (2024).","DOI":"10.1002\/cam4.70166"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Hakozaki T, Nolin-Lapalme A, Kogawa M, Okuma Y, Nakamura S, Moreau-Amaru D, Tamura T, Hosomi Y, Takeyama H, Richard C, Hosokawa M, Routy B. Cancer cachexia among patients with advanced non-small-cell lung cancer on immunotherapy: an observational study with exploratory gut microbiota analysis. <i>Cancers<\/i>, <b>14<\/b>, 5405 (2022).","DOI":"10.3390\/cancers14215405"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/5\/49_b25-00791\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:25:45Z","timestamp":1778901945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/5\/49_b25-00791\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00791","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"article-number":"b25-00791"}}